Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 10609 - 10616 of 12007 results
It’s The Most Wonderful Time (For 990 Filings) Of The Year
February 24, 2014| Blog| Viewpoint
A Guide to the FDA's Proposed Social Media Guidance
February 23, 2014| Blog| Viewpoint
"Sophisticated" Breach Exposes 300,000 Student Records at University of Maryland: 3 Questions You Should Ask
February 21, 2014| Blog| Viewpoint
San Francisco Employers – Heads Up, New Rules Governing The Use of Criminal Records
February 21, 2014| Blog| Viewpoint
Complaint from BBB Triggers HarperCollins COPPA-Compliance Measures
February 20, 2014| Blog| Viewpoint
Aloha to CPSC Counsel Joe Martyak & Welcome Back to Gib Mullan, Former CPSC General Counsel & Compliance Director
February 20, 2014| Blog| Viewpoint
2, 4, 6, 8…NFL Cheerleaders Not “Rah Rah-ing” About Pay Rate
February 20, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|